SCHEDULE 13G/A: LCK JNK 1 LLC Discloses 9.5% Stake in Scinai Immunotherapeutics Ltd.

LCK JNK 1 LLC has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Scinai Immunotherapeutics Ltd.'s American Depository Shares.

Summary

• LCK JNK 1 LLC beneficially owns 80,757 American Depository Shares (ADSs) of Scinai Immunotherapeutics Ltd.
• This ownership represents 9.5% of the class of securities, based on 3,411,983,584 ordinary shares outstanding as of September 30, 2024.
• Richard J. Kertzman, as the managing member of LCK JNK 1 LLC, is deemed to indirectly beneficially own these securities.
• The reported ownership includes sole voting and sole dispositive power over all 80,757 ADSs.
• The filing notes that the beneficial ownership percentage does not include pre-funded warrants for an additional 80,757 ADSs, which are subject to a 9.99% beneficial ownership limitation upon exercise.
• Future issuances of ordinary shares or ADSs by Scinai Immunotherapeutics Ltd. to third parties are expected to allow additional pre-funded warrants to become exercisable without increasing the reporting person's beneficial ownership percentage.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a strong positive or negative sentiment.

Positives

• The disclosure of a significant 9.5% stake by LCK JNK 1 LLC could be interpreted as a vote of confidence in Scinai Immunotherapeutics Ltd. by a substantial investor.

Risks

• The beneficial ownership limitation of 9.99% on the exercise of pre-funded warrants could restrict the immediate full conversion of these warrants into ADSs.
• Future issuances of ordinary shares or ADSs by Scinai Immunotherapeutics Ltd. to third parties, while potentially enabling the exercise of more pre-funded warrants, could also lead to dilution for existing shareholders.

Future Outlook

The document indicates that future issuances of ordinary shares or ADSs by Scinai Immunotherapeutics Ltd. to third parties are anticipated. These future issuances are expected to facilitate the exercisability of additional pre-funded warrants held by the reporting person, without increasing their current beneficial ownership percentage beyond the stated limit.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Richard J. Kertzman, Sole Member of LCK JNK 1 LLC)

Industry Context

This Schedule 13G filing is a standard disclosure in the U.S. financial markets, indicating a significant ownership stake in a publicly traded company. For biotechnology or pharmaceutical companies like Scinai Immunotherapeutics, such filings provide transparency regarding major investors, which can be a signal of investor confidence or strategic interest, though this specific filing does not provide operational or strategic details beyond ownership.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant investor's stake. Future issuances by the company could lead to dilution for existing shareholders, while the exercise of pre-funded warrants could bring additional capital to the company.

Key Dates

Keywords

Scinai Immunotherapeutics, LCK JNK 1 LLC, beneficial ownership, Schedule 13G, American Depository Shares, ADS, ordinary shares, Richard J. Kertzman, equity stake, SEC filing